

Wellnex's Strategic Advantage from the Sigma-Chemist Warehouse Merger

The merger between Sigma Healthcare Limited (Sigma) and Chemist Warehouse Group (CWG) represents one of the most significant consolidations in the Australian pharmaceutical industry. This transaction will create a vertically integrated entity that combines Sigma's extensive pharmaceutical wholesale and distribution network with Chemist Warehouse's dominant retail presence.

Overview of the Merger

Sigma Healthcare announced its intention to acquire 100% of CWG's issued shares in a cash-and-stock transaction in the backdoor listing. The ~A\$8.8 billion deal includes a \$700 million cash payment and the issuance of Sigma shares, resulting in CWG shareholders owning 85.75% of the merged entity. Sigma will remain the publicly listed parent company, retaining its ASX listing.

Key Transaction Details

- ❑ Transaction Structure: Cash and Sigma share issuance
- ❑ Ownership Structure: CWG shareholders (85.75%), Sigma shareholders (14.25%)
- ❑ Acquisition Cost: \$700 million in cash + Sigma shares

Market Leadership & Vertical Integration

The merger creates a dominant player in the Australian pharmaceutical industry with 880 franchised retail pharmacies and over 3,500 wholesale customers. The combined entity benefits from Chemist Warehouse's leading market position in discount pharmacy retailing and Sigma's sophisticated wholesale distribution capabilities.

The merger presents a significant opportunity for Wellnex Life Limited, given its long-standing partnership with Chemist Warehouse. This consolidation strengthens the retail and wholesale pharmaceutical ecosystem, creating new avenues for Wellnex to expand its distribution, enhance product visibility, and leverage strategic synergies.

Expanded Distribution & Retail Presence

This merger presents Wellnex with significant opportunities to expand its market presence and enhance operational efficiency. With multiple product placements already in Chemist Warehouse stores, Wellnex gains access to a larger and more streamlined supply chain, reducing lead times and improving logistics. Additionally, the expanded reach of the merged entity allows for greater retail shelf space, increasing the visibility of Wellnex's owned brands, including **Pain Away, Wakey Wakey, Nighty Night, The Iron Company, and Mr Bright**. This strategic alignment also accelerates Wellnex's national and international expansion, supporting its growth into key markets such as New Zealand, Ireland, Dubai, and China.

Kristofer Gordon, CFA
Head of Research,
+61 2 8288 6900
kristofer@barclaypearce.com.au

James Whelan
Managing Director,
Wealth Management
+61 2 8288 6912
james@barclaypearce.com.au

Andrew Murphy
Head of Institutional Services,
Wealth Management
+61 2 8288 6917
andrewm@barclaypearce.com.au

Trent Primmer
Director of Deal Distribution,
Wealth Management
+61 2 8288 6911
trent@barclaypearce.com.au

Michael Jeffery
Director,
Corporate Finance
+61 2 8288 6905
michael@barclaypearce.com.au

Jack Colreavy, CFA
Associate Director,
Corporate Finance
+61 2 8288 6900
jack@barclaypearce.com.au

Joint Venture with Chemist Warehouse in Medicinal Cannabis

Wellnex Life has partnered with Chemist Warehouse in a joint venture to launch the Wellness Life medicinal cannabis brand, positioning itself as a leader in the rapidly growing medicinal cannabis market.

This collaboration provides Wellnex with several key advantages, including integration with telehealth services, enabling InstantConsult to streamline prescriptions for Wellness Life products.

Increased Private Label and Exclusive Brand Opportunities

Chemist Warehouse has significantly expanded its private label and exclusive brand portfolio, creating a strategic opportunity for Wellnex to leverage Sigma's advanced distribution capabilities. Through this partnership, Wellnex can develop and launch new products under Chemist Warehouse's private label, benefiting from exclusive collaborations.

Additionally, increased R&D efforts—particularly in wellness, functional foods, and pharmaceutical products—will drive innovation and product differentiation. This alliance also opens the door for enhanced branding and co-marketing initiatives, allowing Wellnex to tap into Chemist Warehouse's extensive advertising reach to maximize visibility and consumer engagement.

Conclusion

The Sigma-Chemist Warehouse merger strengthens Wellnex's positioning in the pharmaceutical and wellness market. With increased distribution efficiency, stronger supplier influence, and expanded retail exposure, Wellnex is well positioned to benefit significantly from this industry shift.

Disclaimer

This Research is intended solely for the information of the particular person to whom it was provided by BPCAM and should not be relied upon by any other person. The information in this Research does not purport to be complete nor does it contain all the information which a prospective investor may require. The information contained in this Research is general in nature and does not constitute advice nor a recommendation to deal. This Research does not constitute specific advice and does not take into account financial objectives or situation of an investor. All and any recipients of this Research acknowledge and agree that they must conduct and have conducted their own due diligence investigation and have not relied upon any representations of BPCAM, its officers, employees, representatives or associates. BPCAM has not independently verified the information contained in this Research. BPCAM assumes no responsibility for updating any information, views or opinions contained in this Research or for correcting any error or omission which may become apparent after the Research has been issued. BPCAM does not give any warranty as to the accuracy, reliability or completeness of advice or information which is contained in this Research. Except insofar as liability under any statute cannot be excluded, BPCAM and its officers, employees, representatives or associates do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this Research or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this Research or any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party. This Research must not be distributed or released in the United States. It may only be provided to persons who are outside the United States and are not, and are not acting for the account or benefit of, "US Persons" in connection with transactions that would be "offshore transactions" (as such terms are defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). Any securities mentioned in the Research have not been and will not be registered under the Securities Act or the securities laws of any state or jurisdiction of the United States, and may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws in the United States or to, or for the account or benefit of, a US Person. This Research does not, and is not intended to, constitute an offer or invitation in the United States, or in any other place or jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or invitation. If you are not the intended recipient of this Research, please notify BPCAM immediately and destroy all copies of this Research, whether held in electronic or printed form or otherwise.

Disclosure of Interest

The Company, its officers, employees, representatives and associates within the meaning of Chapter 7 of the Corporations Act may receive commissions and management fees from transactions involving securities referred to in this Research (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this Research. The Company does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Analyst Certification

The research analyst(s) identified above individually certify that in respect of each security or issuer that the research analyst covers that: this report accurately reflects his or her personal views about any and all of the subject issuer(s) or securities; and no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or views expressed by the research analyst(s) in this report. BPCAM provides research services to its clients. Mr Gordon is a seasoned investment professional. He holds a degree in Economics from Ohio State University, where he specialized in game theory and comparative economics. Kris is also an active Chartered Financial Analyst (CFA) charter holder with the CFA Institute.

Conflicts of Interest

BPCAM does not have material interests in the financial products discussed in this Research Report and it will not receive benefits in relation to the publication of this Research Report. BPCAM manages all Conflicts of Interest in accordance with its Conflicts of Interest Policy. Please contact us if you require any further information.